Schizophrenia

FDA Grants Fast Track Status to Lumateperone for Schizophrenia

By November 20, 2017

In two studies, lumateperone showed a statistically significant separation from placebo on the primary endpoint, the Positive and Negative Syndrome Scale, or PANSS, total score.

Antipsychotic Efficacy Compared in Real-World Schizophrenia Study

June 09, 2017

Risk of rehospitalization substantially lower with long-acting injectables versus oral equivalents